C5AR1 and atypical hemolytic-uremic syndrome: Targeting C5a-C5aR interactions has shown potential for treating various inflammatory diseases.712 Blocking the protein-protein interaction between C5a and C5aR represents a viable strategy for anti-inflammatory therapy.713 Avacopan, an orally available C5aR1 inhibitor, is used as an adjunct to glucocorticoids for treating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis714 and is being tested for conditions like atypical hemolytic uremic syndrome (aHUS), IgA nephropathy, and C3 glomerulonephritis.